# A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor.

> **NCT05717166** · PHASE3 · RECRUITING · sponsor: **David Palma** · enrollment: 180 (estimated)

## Conditions studied

- Metastatic Tumor

## Interventions

- **RADIATION:** Palliative Radiotherapy
- **DRUG:** Chemotherapy
- **DRUG:** Hormone therapy
- **DRUG:** Immunotherapy
- **DRUG:** Targeted Systemic Therapy
- **OTHER:** Observation
- **RADIATION:** Stereotactic Ablative Radiotherapy
- **PROCEDURE:** Surgery
- **OTHER:** Radiofrequency Therapy (RFA)
- **RADIATION:** Fractionated Radiation

## Key facts

- **NCT ID:** NCT05717166
- **Lead sponsor:** David Palma
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-06
- **Primary completion:** 2029-04
- **Final completion:** 2029-04
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2025-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05717166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05717166, "A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05717166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*